Latest / Pharmacy Podcast Network / Fertility, Pharmacy, and the Future: A Pharmacist’s Role in IVF Care with Dr. Kelly Gonda| MaternalRx
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy podcast Network.
- 0:26Speaker 2: In this episode of Maternal RX, doctor Danielle Plumber interviews
- 0:30Speaker 2: doctor Kelly Ganda, a doctor of pharmacy and fertility nurse practitioner.
- 0:34Speaker 2: Doctor Ganda dives deep into how pharmacists can support IVF patients,
- 0:39Speaker 2: covering everything from understanding hormones and load to high tech
- 0:42Speaker 2: treatment options, to navigating medication costs and insurances. We also
- 0:46Speaker 2: explore pcos oosite freezing, male fertility, medication safety, and the
- 0:52Speaker 2: critical need for pharmacist advocacy and reproductive care.
- 0:55Speaker 1: Hi there, this is Danielle Plumber, pharmacist and host of
- 0:59Speaker 1: the Maternal Aura this podcast. I am so excited for
- 1:02Speaker 1: today's guest, doctor Kelly Ganda, because of her unique background
- 1:07Speaker 1: and everything the incredible work she is doing in the
- 1:10Speaker 1: world of infertility. So Kelly is not only a pharmacist
- 1:14Speaker 1: but also a fertility nurse practitioner. She started her career
- 1:17Speaker 1: as an NP and found that pharmacist, particularly new ones,
- 1:22Speaker 1: and I would like to add most pharmacists myself included,
- 1:25Speaker 1: do not often understand the IVF protocols and adjunct therapies
- 1:30Speaker 1: that are prescribed regularly to patients.
- 1:32Speaker 3: So Kelly is on here today to share all her.
- 1:36Speaker 1: Insights about being a nurse practitioner, a pharmacist, and a
- 1:40Speaker 1: specialist in the space of in vitro fertilization.
- 1:44Speaker 3: So Kelly, thank you so much for joining me today.
- 1:48Speaker 4: It's a pleasure to be here.
- 1:49Speaker 5: Thank you for letting me join your podcast and share
- 1:54Speaker 5: my insights.
- 1:56Speaker 3: And there's so many insights.
- 1:57Speaker 1: Again, like you said, and I just mentioned production, there
- 2:00Speaker 1: is so much we don't know.
- 2:02Speaker 3: You and I had a little chat prior.
- 2:04Speaker 1: To me hitting record because we both went to the
- 2:06Speaker 1: same pharmacy school.
- 2:07Speaker 3: And I mentioned that.
- 2:09Speaker 1: I never learned any of this and thought it did
- 2:11Speaker 1: the curriculum change? And you said, not only is it
- 2:14Speaker 1: not taught in pharmacy school, it's not taught to nurse
- 2:17Speaker 1: practitioners either, right, And you also started to explain to me,
- 2:22Speaker 1: and I told you, hold your thought. There's differences in
- 2:24Speaker 1: the types of nurse practitioners, so why don't we start there.
- 2:28Speaker 5: Sure, So there's a family nurse practitioner which can take
- 2:31Speaker 5: care of the whole spectrum, so kids to older adults.
- 2:36Speaker 5: There's pediatric nurse practitioners who focus primarily on kids under
- 2:41Speaker 5: the age of eighteen. And then there's women's health nurse practitioners,
- 2:47Speaker 5: So women's health nur's practitioners are primarily focused in the
- 2:51Speaker 5: women's face. And from what I hear, a lot of
- 2:55Speaker 5: my peers in the fertility space were women's health nurs practitioners.
- 3:00Speaker 5: They didn't even get the full understanding of fertility medications protocols.
- 3:07Speaker 5: They got the very basic, which was like plumid and
- 3:12Speaker 5: injectable menotropans, and that's it.
- 3:15Speaker 1: In my previous life as a retail pharmacy manager, that's
- 3:19Speaker 1: about all I knew as well. So I have had
- 3:22Speaker 1: the fortunate opportunity to collaborate with other pharmacists in this space.
- 3:28Speaker 3: So I just want to give a little shout out
- 3:29Speaker 3: to them.
- 3:30Speaker 1: A Lease Fields whose podcast is differentily pharmacist podcasts, and
- 3:35Speaker 1: I interviewed Katie would and integrated fertility coach and actually
- 3:39Speaker 1: learned a lot about her. So you can go back
- 3:41Speaker 1: to September twenty twenty three to.
- 3:43Speaker 3: Hear that interview.
- 3:44Speaker 1: But you're bringing a whole new perspective because you've actually
- 3:47Speaker 1: worked in this space in many capacities, not just as
- 3:50Speaker 1: an MP and a pharm d but also in the
- 3:53Speaker 1: pharmaceutical industry, so can really.
- 3:56Speaker 3: Bridge that gap.
- 3:57Speaker 1: There's a lot of misperceptions to what these different industries
- 4:01Speaker 1: and different roles play into the success of a woman
- 4:05Speaker 1: going through this and the support her family.
- 4:07Speaker 3: Does or does that does not have.
- 4:09Speaker 1: And I would love for you to walk us through
- 4:11Speaker 1: the process of somebody undergoing IVF and what role would
- 4:16Speaker 1: a pharmacist play in ensuring safety and success.
- 4:20Speaker 5: Sure, so when a patient comes to the clinic, they
- 4:25Speaker 5: go through the diagnostic process, she and her partner will
- 4:29Speaker 5: do that the actual intended parents and when the workup
- 4:35Speaker 5: is done, there's a decision is it are they going
- 4:38Speaker 5: to do maybe lower tech? Are they going to go
- 4:41Speaker 5: to IVF. Usually if they're over age thirty five, they
- 4:45Speaker 5: are pushed IVF more quickly just because of the advanced
- 4:48Speaker 5: maternal age. If they're under thirty five, they might try
- 4:51Speaker 5: other things. And I guess I'll start there because if
- 4:54Speaker 5: they're starting at the clone mid level, which is what
- 4:57Speaker 5: pharmacists know, like you said, they meet taking lomid, but
- 5:02Speaker 5: they also may be taking letrozol also known as femara,
- 5:07Speaker 5: And the reason for that is there was a twenty
- 5:10Speaker 5: thirteen paper that was the price paper at ASRM that
- 5:15Speaker 5: compared clmid and electrosol. They work very differently. Clonmid is
- 5:21Speaker 5: a non stoidal anti estrogenic and letrozol is an aromatase inhibitor, but.
- 5:28Speaker 4: Both has kind of the same effect as far as.
- 5:33Speaker 5: Encouraging the pituitary to secrete FSH right, which is what
- 5:39Speaker 5: you want. You want FSH to grow. Follicles are which
- 5:44Speaker 5: hold the egg on the ovary and increased chances of pregnancy.
- 5:50Speaker 5: So I think a lot of new pharmacists will get
- 5:53Speaker 5: in order for electrozol, and.
- 5:56Speaker 4: Letrozol is also used as we know in.
- 5:58Speaker 5: Breast cancer, so they think what in the world is
- 6:01Speaker 5: going on with this order and.
- 6:03Speaker 4: Is it correct? Right?
- 6:05Speaker 5: So yeah, so that's that's one piece. But again that's
- 6:11Speaker 5: used in lower tech, so that's not in vitro fertilization.
- 6:17Speaker 5: That's intrauterine insemination where they'll take the medication and around
- 6:24Speaker 5: the type of ovulation of sperm is inserted into the
- 6:28Speaker 5: uterine cavity at that time.
- 6:31Speaker 4: So that's what they consider low tech.
- 6:33Speaker 5: If they're going into IVF, they will have a protocol
- 6:39Speaker 5: that's assigned them but there's a lot more to that
- 6:42Speaker 5: because yes, we're still going to have the same look
- 6:45Speaker 5: for the same effect. We're going to increase the number
- 6:47Speaker 5: of ovarian follicles that hold theocyte with FSH. But when
- 6:53Speaker 5: you're doing with IVF, you want to grow a bunch
- 6:57Speaker 5: of follicles at once, and in a normal cycle, you
- 7:03Speaker 5: there would be a dominant follicle that would be selected
- 7:07Speaker 5: and there would.
- 7:08Speaker 4: Be one or sometimes two. Sometimes twins happen.
- 7:12Speaker 5: But we're not meant to have all of our follicles.
- 7:17Speaker 5: I had my one of my favorite specialists is we're
- 7:20Speaker 5: not meant to have letters.
- 7:21Speaker 4: We're meant to have babies one at a time. Right.
- 7:25Speaker 5: So what there's medications that have to quiet the hypothalamus, right,
- 7:32Speaker 5: So we want to keep that quiet because we want
- 7:35Speaker 5: to do the work exogenously with exogenous f SH. The
- 7:40Speaker 5: other medication that people hear about a lot, it's known
- 7:43Speaker 5: as menopure, but it's a human menopausal gannatotropin and it's
- 7:48Speaker 5: got FSH and LH. It is one of the low
- 7:52Speaker 5: tech products, is what you'd hear, because the FSH products
- 7:57Speaker 5: are recombinant avor combinant technology, but the menopure is comes
- 8:05Speaker 5: from the urine of menopausal women. And the reason for
- 8:10Speaker 5: that is because when women go through the menopausal transition,
- 8:14Speaker 5: the pituitary kind of freaks out a little bit and
- 8:16Speaker 5: starts to kick out a whole bunch of f SH
- 8:19Speaker 5: because the ovaras are not working as well. So the
- 8:24Speaker 5: pituitary kicks out a lot of f SH, kicks out LH,
- 8:27Speaker 5: and it also kicks out small amounts of.
- 8:31Speaker 4: hCG, which is interesting.
- 8:33Speaker 5: People don't always know the difference between placental hCG and
- 8:39Speaker 5: pituitary HGG. The earliest fertility medications back in the day
- 8:44Speaker 5: perganal b MV Serruno had that product, but that was
- 8:49Speaker 5: placential HGG, so it was kind of used as a
- 8:56Speaker 5: you know, it was used for a really long time.
- 8:57Speaker 5: It wasn't very pure. Patients had weltz. It's an im product.
- 9:03Speaker 5: So I started an IVF. Perganal is still in the market,
- 9:08Speaker 5: so I'm kind of a dinosaur. It quickly left the
- 9:11Speaker 5: market as soon as I entered. And that's when the
- 9:14Speaker 5: DNA were combinant. That was nineteen ninety eight, so dating myself,
- 9:18Speaker 5: but that's uh, so you started to see these higher
- 9:22Speaker 5: tech products. So you're seeing these DNA recombinant technology for FSH.
- 9:26Speaker 5: So you quickly saw two drugs hit the market that
- 9:30Speaker 5: were in that space, right, just bolotrope and alpha and
- 9:34Speaker 5: hoolotropin beta. But the drugs that they used to wyat
- 9:38Speaker 5: the pituitary is lubron, which is not even approved for
- 9:42Speaker 5: that purpose. Lubron, we know it's used in fibroid therapy sometimes,
- 9:49Speaker 5: you know, for those types of things when you want
- 9:52Speaker 5: to I guess induce a pseudomenopause is what they used
- 9:56Speaker 5: to call it, you know, when they use it for
- 9:59Speaker 5: fiber It's so there's there's use of lubron.
- 10:04Speaker 4: To quiet the pituitary and then there's another drug that's it.
- 10:08Speaker 5: So lubron is a g nrh agonist and there's a
- 10:12Speaker 5: g N rh antagonist. There are two of them on
- 10:15Speaker 5: the market actually, but the antagonist is works a little
- 10:20Speaker 5: bit different.
- 10:21Speaker 4: It just kind of sits on the receptor where.
- 10:23Speaker 5: Lubron completely desensitizes the receptors on the pituitary. So yeah,
- 10:29Speaker 5: this very quiet pituitary that we're using lubron or your antagonists,
- 10:35Speaker 5: and then you're giving FSH and sometimes in combination with
- 10:40Speaker 5: menipure the HMG human menopausal get entotropen and then you
- 10:45Speaker 5: continue to give that. I guess we just call it
- 10:48Speaker 5: down regulation, so the down regulation medications of the pituitary.
- 10:52Speaker 5: And then you're giving the exaginists f SH, so you're allowed.
- 10:56Speaker 5: So you're keeping this cohorta follicles that are growing on
- 11:00Speaker 5: the ovary and you want to get a lot of them, right,
- 11:02Speaker 5: so you do because you don't have them dying off
- 11:05Speaker 5: to a tresia like they would.
- 11:06Speaker 4: An a normal side.
- 11:07Speaker 5: So then after once they get to this I guess,
- 11:13Speaker 5: the follicles get to the size the doctor wants, they
- 11:16Speaker 5: have to induce. They have to either give they have
- 11:21Speaker 5: to give an hCG product or sometimes they can actually
- 11:25Speaker 5: give lupron as a trigger, which is interesting because it
- 11:28Speaker 5: has kind of that flair effect that like initial release
- 11:33Speaker 5: of FSH and LH from the pituitary and that kind
- 11:36Speaker 5: of triggers a kind of the same response and then
- 11:41Speaker 5: they'll retrieve the ocides. But they need that trigger to
- 11:46Speaker 5: allow them to be able to pull the ocite out
- 11:50Speaker 5: of the follcle kind of loosens it up a little
- 11:53Speaker 5: bit so they can do the ocide retrieval and pull
- 11:56Speaker 5: those ocides out. And then that's why it's called in
- 12:00Speaker 5: vitro fertilization because the rest happens outside the body, but
- 12:05Speaker 5: when they pull site out of the follicle, they're also
- 12:10Speaker 5: pulling a lot of the other cells, like the granulosa
- 12:14Speaker 5: cells and the fecal cells that normally, like in a
- 12:17Speaker 5: corpus lutium situation, secrete progesterone. So these women have to
- 12:23Speaker 5: also go through after their osite retrieval and they are
- 12:30Speaker 5: to support a pregnancy, they'll need to take progesterone, and
- 12:34Speaker 5: unfortunately there's not a lot of options. There's progesterone and oil,
- 12:40Speaker 5: which is an im injection, and then there are vaginal
- 12:44Speaker 5: progesterone products. So I think that pharmacists will see the
- 12:49Speaker 5: corenone and there's another one under the name of endometron
- 12:54Speaker 5: that are the vaginal products. The progesterone and oil is
- 12:59Speaker 5: pretty ugly in terms of the i AM and women.
- 13:06Speaker 4: Take it for ten weeks.
- 13:07Speaker 5: They have to take it until the ludio placental shift,
- 13:12Speaker 5: so it's a long time to take progesterone injections that are.
- 13:17Speaker 4: I AM and so I think that this is where.
- 13:23Speaker 5: There's a lot of other things that are given in
- 13:26Speaker 5: the cycle. So all of that would make sense, Like
- 13:28Speaker 5: if you explain that to a pharmacist, they would be like,
- 13:32Speaker 5: you know, we know pharmacists are very well trained, they
- 13:34Speaker 5: have the biochemistry, they have all these things they would
- 13:38Speaker 5: be able to that.
- 13:39Speaker 4: Would track with a pharmacist.
- 13:43Speaker 5: I think where things get kind of a little bit
- 13:47Speaker 5: confusing are the adjunct therapies which I mentioned earlier when
- 13:52Speaker 5: we were chatting, and these come in the form of
- 13:56Speaker 5: growth hormone, and growth hormone is kind of sensitizes that receptor,
- 14:02Speaker 5: the f sate receptor.
- 14:04Speaker 4: That's the thought process, and there's an a thought process.
- 14:06Speaker 5: That there are shortages in growth hormone as women get older.
- 14:11Speaker 5: So that's just one piece of it. Another piece of
- 14:14Speaker 5: it they would give. And this sometimes this threw me
- 14:19Speaker 5: as a new nurse practitioner. I had a prescription given
- 14:24Speaker 5: from a doctor for met Foreman, which is a diabetes medication.
- 14:29Speaker 4: Right.
- 14:30Speaker 5: So, but there are some women who have the diagnosis
- 14:35Speaker 5: of polycystical variant syndrome, and so you want to reduce
- 14:38Speaker 5: their insulin resistance and that's that's.
- 14:41Speaker 4: Given in the cycle. And it does make a difference
- 14:45Speaker 4: oftentimes that can be.
- 14:46Speaker 5: Given in the low tech cycles because if they have PCOS,
- 14:52Speaker 5: and that's there are polycystical variants in syndrome or PCOS there.
- 14:59Speaker 4: If that's they are only diagnosis.
- 15:01Speaker 5: And they're young enough, you can give met foreman and
- 15:03Speaker 5: do an interuterian insumination cycle, so you'd see it more
- 15:08Speaker 5: with your clonit or latrosol, and then you'd have your
- 15:11Speaker 5: met forman. When it comes to IVF cycles, you see
- 15:15Speaker 5: it maybe a little bit less. However, if they have
- 15:17Speaker 5: a PCOS diagnosis, you might see that. Unfortunately, the evidence
- 15:22Speaker 5: is that it doesn't increase the chances of live birth.
- 15:27Speaker 5: It may increase the chance of pregnancy, which is really interesting.
- 15:31Speaker 5: I think those PCUS patients sometimes walk around with the
- 15:35Speaker 5: high blood sugar and an elevated hemoglobein a one C
- 15:42Speaker 5: and that's not conducive to pregnancy, so they can have
- 15:45Speaker 5: miscarriages unfortunately.
- 15:49Speaker 3: So wow, Okay, this is a lot of information.
- 15:52Speaker 1: So I'm definitely going to go back and re listen
- 15:54Speaker 1: to this a whole bunch of times.
- 15:55Speaker 4: Okay, Yeah, I think a lot.
- 15:58Speaker 1: Of Farman says like me, were very visual, so as
- 16:00Speaker 1: you're speaking through the process, you can imagine, like I'm
- 16:03Speaker 1: picturing that what they call in the textbook world a cartoon, right,
- 16:09Speaker 1: the visualization of what is exactly happening with these different hormones,
- 16:14Speaker 1: with the ocytes and what gets put in and taken
- 16:18Speaker 1: out and developed. And you mentioned a few things I
- 16:20Speaker 1: wanted to swing back too. One was we're not meant
- 16:24Speaker 1: to have litters. So I don't know if you or
- 16:26Speaker 1: anybody else and that might be listening.
- 16:28Speaker 3: Can remember this. And I actually thought it was further
- 16:31Speaker 3: back in time. I just went back to Google and
- 16:33Speaker 3: looked it up.
- 16:34Speaker 1: But two thousand and nine, Nadya Suliman had the first
- 16:40Speaker 1: surviving octuplet, so eight babies. I would like to go
- 16:45Speaker 1: back after this call and after this interview and see
- 16:48Speaker 1: how they did. In the end, I'm looking at she
- 16:50Speaker 1: actually is a grandma now, so quite wild, but.
- 16:56Speaker 3: I just remember those pictures of her belly.
- 16:58Speaker 1: Carrying these eight babies, and the care that was involved,
- 17:00Speaker 1: the cost that was involved. Because I do want to
- 17:03Speaker 1: speak to you about the financial implications and legislation that's happening.
- 17:07Speaker 3: But before we do.
- 17:09Speaker 1: That, so much to understand and exactly what's happening. And
- 17:13Speaker 1: when you said low tech or high tech, I love
- 17:16Speaker 1: how that's divided because it really gives me a clear
- 17:19Speaker 1: image and picture of what can we do to understand
- 17:22Speaker 1: and remember so when we meet these patients, either in
- 17:25Speaker 1: the retail space or in the hospital space or elsewhere,
- 17:28Speaker 1: we might be working with them as coworkers. In fact,
- 17:32Speaker 1: my senior tech when I was a pharmacy manager in
- 17:35Speaker 1: a retail setting, would have to seven o'clock every night
- 17:39Speaker 1: run away off into the bathroom to give herself that
- 17:42Speaker 1: injection because I would I did.
- 17:43Speaker 3: At the time.
- 17:44Speaker 1: I'm like, I don't want to give you your injection,
- 17:46Speaker 1: And I was fine doing immunizations, but I knew nothing
- 17:49Speaker 1: about IVF and she was my technician and there she was,
- 17:53Speaker 1: and I was thinking, oh my gosh, she really really wants.
- 17:56Speaker 3: To have this baby to be going through that.
- 17:58Speaker 1: And I think most people don't understand the process emotionally, physically,
- 18:03Speaker 1: and circling back to financially. So you mentioned briefly the
- 18:08Speaker 1: costs involved. Where does somebody begin to understand how do
- 18:12Speaker 1: you afford this?
- 18:12Speaker 3: Does insurance cover it? Are their grants or agencies or
- 18:16Speaker 3: I don't know. Sometimes I'll see work benefits that help out.
- 18:19Speaker 1: Well, can you tell us about somebody who realizes that
- 18:22Speaker 1: at a point in life that this might be something
- 18:26Speaker 1: that they would need to grow their family.
- 18:31Speaker 5: So currently we see more coverage either from the fully
- 18:36Speaker 5: insured insurance companies that come from with your employer insurance,
- 18:41Speaker 5: and we sometimes see it through state mandates. So there
- 18:46Speaker 5: are Illinois has a very good state mandate. Massachusetts have
- 18:51Speaker 5: state mandates and they have very generous benefits, so they'll
- 18:54Speaker 5: have and what they do is they do the number
- 18:57Speaker 5: of cycles, so it's not capped with you can only
- 19:02Speaker 5: take this many drugs or this many you know, but
- 19:05Speaker 5: you could do four cycles in this for example, the
- 19:08Speaker 5: state of Illinois which I worked in, it's four cycles,
- 19:11Speaker 5: and then if you get pregnant on your last cycle,
- 19:13Speaker 5: you get another additional two IVF cycles, so that would
- 19:17Speaker 5: be six IVF cycles. And if they're freezing embryos, they
- 19:21Speaker 5: would have frozen embryo transfer cycles that they could do subsequently.
- 19:26Speaker 5: So these would all be covered, fully paid, fully paid
- 19:30Speaker 5: with the medications, fully paid with the physicians. And the
- 19:34Speaker 5: reason why that happened and we're going to see it
- 19:37Speaker 5: in other states. Actually, California is getting ready to pass
- 19:41Speaker 5: a state mandate, which is going to be interesting because
- 19:45Speaker 5: it's the fifth largest economy in our world and all
- 19:48Speaker 5: of a sudden we're going to have all of these patients,
- 19:51Speaker 5: and it's the state employees of California that would be covered,
- 19:56Speaker 5: which would mean school teachers. And I would used to
- 20:00Speaker 5: have very busy summers in the IVF clinic because the
- 20:03Speaker 5: school teachers would come through to get their IVF cycles then.
- 20:07Speaker 4: So it's very interesting.
- 20:08Speaker 5: But you know, these these mandates are very generous and
- 20:12Speaker 5: they help a lot.
- 20:15Speaker 4: Some people move to a state.
- 20:18Speaker 5: Some people can be in a state not for example,
- 20:22Speaker 5: not Illinois, but if their insurance was from the state
- 20:26Speaker 5: of Illinois, so that the written agreement with the insurance
- 20:29Speaker 5: company was through the state of Illinois, they would get coverage.
- 20:33Speaker 5: And so you see this kind of all over the country,
- 20:36Speaker 5: and it throws pharmacists because we know in the pharmacy
- 20:40Speaker 5: space there's all of a sudden this sometimes prior authorization. Okay,
- 20:46Speaker 5: there's coverage. I don't understand where the coverage is in
- 20:49Speaker 5: pharmacy school. My friends and I used to call each other,
- 20:52Speaker 5: we had a group name. We used to call each
- 20:54Speaker 5: other the third party Rejects, because you know, you get
- 20:57Speaker 5: that rejection on the pharmacy and so you get all
- 21:00Speaker 5: of these stipulations and the pharmacists have to you know,
- 21:03Speaker 5: kind of learn that the fertility pharmacists are pretty well
- 21:07Speaker 5: versed in it. But if for some reason it comes
- 21:10Speaker 5: to a retail because for example, like CBS has care
- 21:16Speaker 5: Mark and they have a very big fertility.
- 21:20Speaker 4: Offering, right, so some of the employers.
- 21:23Speaker 5: Will choose care Mark as a PBM and that will
- 21:26Speaker 5: be so that would mean their fertility benefits would come
- 21:29Speaker 5: through CBS. So that could sometimes end up in the
- 21:32Speaker 5: retail space. With the fertility of our pharmacists, it's not
- 21:36Speaker 5: a fertility pharmacist, right, just doing everything, and then all
- 21:40Speaker 5: of a sudden they have this you know, this order
- 21:42Speaker 5: and sometimes they have to transfer it to a specialty space.
- 21:45Speaker 4: So, you know, and nurses don't know. They don't know.
- 21:49Speaker 5: They just send the order where they're supposed to send it,
- 21:52Speaker 5: and it could end up in the hands of sometimes
- 21:54Speaker 5: someone who doesn't know, and then that becomes an intricate
- 22:00Speaker 5: because the patient gets evolved and then there's delays in
- 22:02Speaker 5: meds and so that becomes difficult.
- 22:06Speaker 4: So I think that.
- 22:08Speaker 5: Primarily when I started in this space, the patient was
- 22:12Speaker 5: the payer almost one hundred percent, so they were paying,
- 22:17Speaker 5: they were financing their homes right, taking out helocks to finance.
- 22:23Speaker 4: It and or borrow money from family or I.
- 22:27Speaker 5: Had actually had patients who said, we're not buying We
- 22:30Speaker 5: had eight thousand dollars saved for a down payment for
- 22:33Speaker 5: a home, but we are not buying a home until
- 22:37Speaker 5: we have a baby or pregnant. So I watched them
- 22:41Speaker 5: run through that entire savings and then still.
- 22:46Speaker 4: Not end up with a baby.
- 22:47Speaker 3: Wow.
- 22:49Speaker 5: Now there's lots of past parenthoods, so they didn't end
- 22:52Speaker 5: up with the baby. Through IDF, they can go through
- 22:54Speaker 5: the adoption process. There's so many There were so many options,
- 22:58Speaker 5: but people are very attached to their DNA. They want
- 23:02Speaker 5: to have their baby right. So that's very sad. It
- 23:06Speaker 5: was very sad to see that. As insurance companies have
- 23:09Speaker 5: become more and more open to this, and sometimes they're
- 23:14Speaker 5: forced through state mandate. But sometimes, you know, sometimes it's
- 23:17Speaker 5: a talent retention you see. You know, Wow, if we
- 23:21Speaker 5: have fertility benefits, more people are more likely to come
- 23:24Speaker 5: work here.
- 23:25Speaker 4: In fact, I saw a.
- 23:27Speaker 5: Man once quit his job he was the male partner,
- 23:32Speaker 5: and go to a FedEx because at that time, FedEx had.
- 23:37Speaker 4: Great fertility benefits.
- 23:39Speaker 5: So he quit his job, went to FedEx, started at
- 23:42Speaker 5: FedEx and got fertility benefits.
- 23:44Speaker 4: So I mean there was a lot of that going on.
- 23:46Speaker 5: So and I think employers caught on Silicon Valley, caught
- 23:52Speaker 5: on right, and all of a sudden, not only did
- 23:55Speaker 5: you have IVF benefits, but they were sending benefits for
- 24:02Speaker 5: younger women to freeze their oocytes.
- 24:04Speaker 4: And essentially it's a cycle.
- 24:06Speaker 5: They have to take the FSH, they have to take
- 24:09Speaker 5: all the meds that I mentioned before, but it's a
- 24:12Speaker 5: lot of money that So a twenty nine year old
- 24:16Speaker 5: woman who's working and hasn't found her partner and is
- 24:20Speaker 5: worried about her fertility or even you know, in early.
- 24:25Speaker 4: Thirties, you know, the ticking clock kind.
- 24:29Speaker 5: Of thing was there. Now you know, we can vitrify oocytes.
- 24:33Speaker 5: Oocytes can go from a liquid to a glass state
- 24:36Speaker 5: in forty five seconds with the vitrification techniques that they have,
- 24:40Speaker 5: which means ice crystals don't form on the outside of
- 24:45Speaker 5: the oocyte which caused DNA damage.
- 24:49Speaker 4: So these oocytes are they survive.
- 24:51Speaker 5: But the ASRM eventually said that oosit freezing was not experimental,
- 24:57Speaker 5: it was an offer that can be given. So you
- 25:02Speaker 5: saw all these women in Silicon Valley with these benefits
- 25:05Speaker 5: and then other employers have caught on and offer it,
- 25:09Speaker 5: and so, you know, there was a little bit of
- 25:11Speaker 5: criticism thrown around, like, well, are you trying to keep
- 25:14Speaker 5: these women in the workforce longer?
- 25:16Speaker 4: Are you, you.
- 25:17Speaker 5: Know, manipulating them to stay? And whether that was true
- 25:22Speaker 5: or not, we don't know. I think it's just they
- 25:24Speaker 5: wanted to offer something to attract talent and Silicon Valley
- 25:28Speaker 5: is a place where you want to do that, right, So,
- 25:32Speaker 5: so you're seeing that more and more. It's still a
- 25:37Speaker 5: financial burden. That being said, it's still a financial burden
- 25:40Speaker 5: on a lot of patients. A lot of people cannot
- 25:43Speaker 5: afford it, or they have an insurance benefit that's ten
- 25:48Speaker 5: thousand dollars lifetime. Okay, so we know it's probably going
- 25:53Speaker 5: to cost them at least ten thousand dollars in the clinic.
- 25:56Speaker 4: But if they use their benefit.
- 25:59Speaker 5: This is where pharmacists can be big help because when
- 26:05Speaker 5: medications go through insurance, they're charged whack prices. The prices
- 26:11Speaker 5: are a lot higher than if they were to pay
- 26:13Speaker 5: out of pocket.
- 26:14Speaker 4: So if they use that ten thousand dollars at the.
- 26:17Speaker 5: Pharmacy, they're only going to have five thousand dollars left
- 26:22Speaker 5: or maybe less or four thousand dollars left in the
- 26:26Speaker 5: clinic and then they're paying out of pocket. So nurses
- 26:31Speaker 5: did catch onto this pretty early and said, okay, is
- 26:35Speaker 5: it going to sound crazy. You have insurance, let's pay
- 26:39Speaker 5: for your your medications out of pocket and use your.
- 26:45Speaker 4: Benefit for the clinic. So they're still paying that.
- 26:49Speaker 5: That's where the financial benefit or the financial strain is
- 26:52Speaker 5: still there even.
- 26:54Speaker 4: In an insurance situation, because.
- 26:57Speaker 5: It falls in the pharmacist and the you know, our
- 27:00Speaker 5: missus giving the patient the final bill, and it's still
- 27:04Speaker 5: a sticker shop, right.
- 27:05Speaker 3: So it's paying right.
- 27:07Speaker 4: And so then a lot of pharmaists understand this too.
- 27:10Speaker 5: They're very as you know, when we're doing our training
- 27:16Speaker 5: in pharmacy school, we're working behind the counter, we're working,
- 27:20Speaker 5: so we know we get that, you know that experience
- 27:24Speaker 5: pretty early on. But it is something that it's like, Okay, great,
- 27:29Speaker 5: the clinic doesn't have to deal with the sticker shop,
- 27:31Speaker 5: but the pharmacist still does. So that's I think a
- 27:36Speaker 5: little bit unfair, but I think it's it's the best
- 27:39Speaker 5: use of their dollars, right, So because if they don't
- 27:42Speaker 5: have if their benefits very limited, it's.
- 27:48Speaker 4: You have to kind of get creative with the finances.
- 27:51Speaker 3: So Kellie, thank you for explaining that.
- 27:54Speaker 1: I work also in oncology, and I see a lot
- 27:56Speaker 1: of parallels there and a lot of it has to
- 27:59Speaker 1: do with the third party, the PBMs. Like you said,
- 28:01Speaker 1: what's a medical benefit, what's a pharmacy benefit? Which pharmacy
- 28:05Speaker 1: you end up getting your medications from what's done in
- 28:07Speaker 1: an office compared to what's done out of the office
- 28:10Speaker 1: or I say office, but fertility clinic. Right, I've actually
- 28:13Speaker 1: worked with embryologists and I've learned. I've seen those containers
- 28:17Speaker 1: where they store all the eggs. It's really really like
- 28:20Speaker 1: science fiction almost, and we've brought it to life literally
- 28:23Speaker 1: to create life, and it's really incredible. It can be
- 28:26Speaker 1: done seamlessly, but the process is much more complex, which
- 28:31Speaker 1: I think is the perception is real is true, and
- 28:34Speaker 1: there's a lot of steps. So thank you for being
- 28:36Speaker 1: in this space and explaining to everyone how what's happening
- 28:40Speaker 1: in the body and then what's happening in the real life.
- 28:42Speaker 1: And what we can do is pharmacists to streamline, simplify
- 28:46Speaker 1: the walkthrough from the beginning to the end.
- 28:49Speaker 3: So if a patient realized this is what we need
- 28:52Speaker 3: to do. How do you even begin to find?
- 28:54Speaker 1: Is it an MD, a DOO and MPAPA a pharmacist?
- 28:59Speaker 3: Where do you begin this search this process?
- 29:02Speaker 4: Yeah, that's a great question.
- 29:04Speaker 5: They you would want to work with board certified or
- 29:09Speaker 5: double board certified because they the fertility physicians go through
- 29:14Speaker 5: a lot of training.
- 29:15Speaker 4: They go through their.
- 29:16Speaker 5: Med school, they go through in obgyn residency and a
- 29:20Speaker 5: three year fellowship that follows the residency. So they're very
- 29:28Speaker 5: well trained they are. They go through their university programs,
- 29:33Speaker 5: they spend a lot of time with the patients, they
- 29:35Speaker 5: spend a lot of time in the clinic, they do
- 29:37Speaker 5: a lot of research, and so that would be the
- 29:40Speaker 5: ideal physician. Unfortunately, the US only graduates about sixty five
- 29:46Speaker 5: of them a year.
- 29:47Speaker 3: Wow.
- 29:48Speaker 4: Yeah, So when you see.
- 29:51Speaker 5: Sixty five of them graduating and two hundred reproductive under
- 29:55Speaker 5: chronology jobs available, it's it's hard. It's very difficult to
- 30:03Speaker 5: fill these positions because we don't have that many fellowship
- 30:06Speaker 5: programs and a fellowship program is very expensive to run
- 30:09Speaker 5: because they're paid well, I mean well well in more
- 30:14Speaker 5: better than residents, right, so they're actually paid throughout their fellowship.
- 30:17Speaker 4: So it's an expensive process and not all. It's a commitment.
- 30:23Speaker 5: You have a fellowship director, you have all of these,
- 30:26Speaker 5: you know, different players who are helping to train these
- 30:29Speaker 5: high tech physicians to get them out into the field.
- 30:34Speaker 4: But that would be so finding one of them.
- 30:36Speaker 5: There's a there's a website called the Society for Assisted
- 30:40Speaker 5: Reproductive Technologies or start start dot org, and if you
- 30:44Speaker 5: go on there.
- 30:45Speaker 4: You can say find a physician.
- 30:47Speaker 5: You can put your town in, you can put the
- 30:50Speaker 5: radius of miles that you're willing to travel, and it
- 30:54Speaker 5: will pull up a list of.
- 30:55Speaker 4: Clinics that are there.
- 30:57Speaker 3: Okay, so I just looked it up.
- 30:59Speaker 1: The number compared to what you said, how many specialists we.
- 31:03Speaker 3: Have in recent years.
- 31:05Speaker 1: So this was out of a citing Pacific Reproductive Center.
- 31:09Speaker 1: The utilization of IVF in the United States has seen
- 31:12Speaker 1: significant growth. According to the CDC, nearly three hundred and
- 31:17Speaker 1: ninety thousand IVF cycles were performed in the United States
- 31:21Speaker 1: in twenty twenty three, more than doubling from twenty eleven.
- 31:25Speaker 1: A website called USA Facts as in twenty twenty one,
- 31:28Speaker 1: two hundred and thirty eight thousand patients initiated over four
- 31:32Speaker 1: hundred and thirteen thousand IVF or other Assisted Reproductive Technology cycles,
- 31:37Speaker 1: so ART cycles. This indicates that many individuals undergo multiple cycles,
- 31:42Speaker 1: as you already mentioned, as a single patient may have.
- 31:45Speaker 3: More than one cycle in a year.
- 31:47Speaker 1: I mean, these numbers are just really astronomical. According to
- 31:51Speaker 1: Cofertility and a few other websites, here it said ivf's
- 31:54Speaker 1: contribution to berths in the US has also increased. In
- 31:57Speaker 1: twenty twenty two, there are ninety one thousand, seven hundred
- 32:01Speaker 1: and seventy one babies born through IVF, accounting for about
- 32:06Speaker 1: two point five percent of all US births that year,
- 32:09Speaker 1: arise from eighty nine thousand in twenty twenty one. So wow,
- 32:16Speaker 1: So this is again circling back. Pharmacists really can play
- 32:20Speaker 1: an important role that missing link to to supporting these
- 32:25Speaker 1: patients understand their medications. And I've seen this in other
- 32:29Speaker 1: disease states as well, where pharmacists are really taking the lead,
- 32:32Speaker 1: and our app's actual apps in many states now.
- 32:38Speaker 3: So if I.
- 32:40Speaker 1: Want to mention another interview I had done with doctor
- 32:43Speaker 1: Ina Lico, it was in February twenty twenty four, aired
- 32:47Speaker 1: May thirty first, twenty twenty four.
- 32:49Speaker 3: If anyone wants to go back and find that on
- 32:51Speaker 3: the Machannel RX podcast.
- 32:52Speaker 1: But she's a specialist in pharmacogenetics and talked about how
- 32:57Speaker 1: can we use PGX to support patients through in feature fertilization.
- 33:03Speaker 3: And there's not a lot of research.
- 33:05Speaker 1: Out there yet, so anyone looking for research projects, I
- 33:08Speaker 1: think this is just an open space that needs to
- 33:11Speaker 1: be stilled.
- 33:12Speaker 5: Yes, and there are several markers that have been found
- 33:17Speaker 5: for implantation, the FSH receptor gene that now is there's
- 33:23Speaker 5: a drug that's being trialed that's really looking at you know,
- 33:28Speaker 5: how does that receptor gene work?
- 33:30Speaker 4: Is it faulty in some patients?
- 33:32Speaker 5: Is that another reason for infertility that we didn't know before.
- 33:36Speaker 5: So yeah, there's a lot in that space, and I think, yes,
- 33:40Speaker 5: we need more research there, so please, you know, research projects, please.
- 33:45Speaker 5: I think we're going to need more fertility pharmacists. So
- 33:48Speaker 5: I think I mentioned before there's some legislation. You know,
- 33:53Speaker 5: if Trump's executive order gets past, there's going to be
- 33:57Speaker 5: more affordability. I think that the they'll be some insurances
- 34:01Speaker 5: that are I guess required to cover IDF. I don't
- 34:05Speaker 5: know what that's going to do to insurance rates in
- 34:06Speaker 5: the United States, but that's another issue. But I mentioned
- 34:10Speaker 5: before the state of California is getting ready to pass
- 34:17Speaker 5: a mandate. I believe in June, but it might be January.
- 34:22Speaker 5: I'm unclear as to when that's going to happen. But
- 34:25Speaker 5: that's a lot of patients. And think about we have
- 34:30Speaker 5: providers shortages, like in terms of the fertility physicians, so
- 34:35Speaker 5: apps are going to have to step up, but we're
- 34:37Speaker 5: going to have to see more pharmacists in this space.
- 34:39Speaker 4: There's not that many and not that many that have
- 34:42Speaker 4: this specialty.
- 34:44Speaker 5: I think that we talked a little bit about how
- 34:47Speaker 5: could a pharmacist.
- 34:48Speaker 4: Who is interested in fertility get trained?
- 34:51Speaker 5: And when I worked in a pharmaceutical company that makes
- 34:55Speaker 5: pharmaceutical medications, I would actually go to pharmacy and pull
- 35:01Speaker 5: up my fertility one on one presentation and you talked
- 35:03Speaker 5: about the needing the images. I have all kinds of
- 35:06Speaker 5: cartoons out there. It's really fun, and I would I
- 35:08Speaker 5: would just walk the pharmacists through it and they would
- 35:12Speaker 5: be like, thank you so much. Now I get like
- 35:14Speaker 5: why these orders are coming through and why you know
- 35:18Speaker 5: this is happening, and why you know certain things that
- 35:20Speaker 5: aren't approved by the FDA are indicated. So that's the
- 35:23Speaker 5: other thing at pharmacies were like, is this drug indicated
- 35:26Speaker 5: for what this doctor's prescribing right or is it.
- 35:29Speaker 4: Being used self label?
- 35:31Speaker 5: Lots of off label use in this area, I would say,
- 35:35Speaker 5: and that's increasing everywhere in other disease states too, as
- 35:38Speaker 5: you mentioned, probably in oncology a little bit of that too.
- 35:41Speaker 4: But yeah, so I think.
- 35:42Speaker 5: There's going to need to be more fertility pharmacies and pharmacists.
- 35:49Speaker 5: But yeah, that is something that if someone was interested
- 35:53Speaker 5: in learning that, you know, they could potentially reach out
- 35:57Speaker 5: or try to, you know, even through a clinic. You know,
- 36:00Speaker 5: find that of those individuals who could help them. Clinics
- 36:05Speaker 5: won't have time to help train pharmacists, so pharmacy questions
- 36:10Speaker 5: won't be answered. But I think that there's so much
- 36:14Speaker 5: that they that pharmacists can contribute to this field that's
- 36:18Speaker 5: not being done. For example, I think that there's patient
- 36:21Speaker 5: counseling that could they could take over counseling in a
- 36:25Speaker 5: way that maybe the apps or physicians and nurses don't
- 36:30Speaker 5: have time to do. And that's so comforting. I think
- 36:34Speaker 5: pharmacists are very trusted in general by the public. We're
- 36:38Speaker 5: one of the more trusted professions. I think that pharmacists
- 36:44Speaker 5: might have a little more time. I'm not going to
- 36:45Speaker 5: say pharmacists have all the time in the world, because
- 36:47Speaker 5: I know they don't.
- 36:49Speaker 1: For some retail space, you know what I retail to
- 36:51Speaker 1: see As the profession changes, I think we're going through
- 36:54Speaker 1: a really big metamorphosis and pharmacists as the retail landscape
- 36:58Speaker 1: changes and big companies like Amazon now we're getting into
- 37:02Speaker 1: pharmacy delivery and lots of mail order.
- 37:06Speaker 3: Pharmacists are now.
- 37:08Speaker 1: Getting into more consulting roles, being able to build for
- 37:11Speaker 1: their consulting services, and this is just a perfect opportunity
- 37:15Speaker 1: for pharmacists to partner with these other practitioners. You mentioned
- 37:20Speaker 1: many times, the interdisciplinary team that really takes a patient
- 37:25Speaker 1: that would need a patient to have a successful journey
- 37:29Speaker 1: feel confident and empowered.
- 37:31Speaker 3: As they go through this process.
- 37:34Speaker 1: It's that pharmacist right that can be there just what
- 37:37Speaker 1: you're doing, Kelly, to understand these are the medications, this
- 37:41Speaker 1: is what to expect and level set those expectations. As
- 37:44Speaker 1: you mentioned, going back to PCOS and the use of
- 37:47Speaker 1: met format and insulin sensitivity and mental health implications that
- 37:53Speaker 1: happened throughout this process. Anyone going through the pregnancy journey.
- 37:58Speaker 1: Regardless of where you are in that journey, it's going
- 38:02Speaker 1: to change your mental state, whether it's for the better
- 38:04Speaker 1: for the worse. And it's it's not a level playing field.
- 38:08Speaker 1: It's a rollercoaster. It's going to keep going up and
- 38:11Speaker 1: down throughout it and even after for those who have
- 38:14Speaker 1: a successful baby, a successful journey and have the baby.
- 38:19Speaker 1: In the end, boy, you're sleep deprived. Your body has
- 38:22Speaker 1: to recover the hormone changes and shifts that you're altering.
- 38:26Speaker 1: Need to regulate themselves again in the end.
- 38:30Speaker 3: And what is regular? What is normal?
- 38:32Speaker 5: Right?
- 38:33Speaker 3: I don't know, does anybody know? Is there such a thing?
- 38:35Speaker 4: Yeah?
- 38:36Speaker 1: Our bodies through life constantly change and this is a
- 38:38Speaker 1: time where we really need support if this is what
- 38:41Speaker 1: we want to do and decide we want to go
- 38:44Speaker 1: on this route. And that's I'm grateful for pharmacists like
- 38:47Speaker 1: Katie would who are there to support anyone going through
- 38:51Speaker 1: this that needs that extra handholding. For pharmacists like you
- 38:55Speaker 1: Kelly who understand all the different low.
- 38:58Speaker 3: Tech, high tech options that are happening.
- 39:01Speaker 1: For Ina who is understanding the pharmacogenetic variations and what
- 39:06Speaker 1: can we do looking at our DNA to help guide
- 39:09Speaker 1: decision making with the medication options that we choose, and
- 39:14Speaker 1: going back to Elisee Fields and sharing the latest data
- 39:17Speaker 1: and guidelines and studies on her podcast Your Fertility Pharmacists
- 39:21Speaker 1: so so much.
- 39:23Speaker 3: So many women. I just named a handful.
- 39:25Speaker 1: There's many other pharmacists and I want to see many more.
- 39:28Speaker 1: And my dream was just to have that pharmacist working
- 39:32Speaker 1: hand in hand with these offices that are providing this care,
- 39:38Speaker 1: having insurances and legislation really smooth out that pathway and
- 39:43Speaker 1: not make it difficult. It's really interesting you said something
- 39:46Speaker 1: I absolutely love. The third party rejects it sounds like
- 39:51Speaker 1: it sounds like a rock band of something, so I'll turn.
- 39:53Speaker 3: It in hand, right.
- 39:54Speaker 1: But that's where we are as pharmacists dealing with pri authorizations.
- 39:58Speaker 3: There is legislation.
- 40:00Speaker 1: The Soriasis Foundation has a website that has a link
- 40:04Speaker 1: to legislation for each state for specialty medications talking about
- 40:11Speaker 1: getting rid of step through therapy or prior authorization. Sometimes
- 40:16Speaker 1: it's just like a letter of medical necessity and I
- 40:18Speaker 1: will tever and reach out to the pharmaceutical company of
- 40:21Speaker 1: the medication that if your provider says this is what
- 40:23Speaker 1: you need and your insurance is kicking back on that
- 40:27Speaker 1: reach out to a pharmaceutical company. They all have patient
- 40:30Speaker 1: support programs, they all have a financial manager might go
- 40:36Speaker 1: buy a different title that can work with the clinic
- 40:39Speaker 1: that is supporting your care. You will not be involved
- 40:42Speaker 1: in that process. They don't speak to you directly, but
- 40:45Speaker 1: they can help move out that paperwork that is required
- 40:49Speaker 1: to get the insurance to cover.
- 40:51Speaker 3: And Kelly, you mentioned what pharmacy do you.
- 40:53Speaker 1: Go to to receive your medications? If it's done in
- 40:57Speaker 1: an out patient setting, can really vary. Ask those questions.
- 41:01Speaker 1: There's case managers that are out there that can help
- 41:04Speaker 1: as well, patient advocates that can help as well, So yes, please.
- 41:08Speaker 4: A lot of advocates.
- 41:10Speaker 5: I also wanted to put a plug in for Mark
- 41:13Speaker 5: Cuban's cost plus strokes. Oh tell me they really are
- 41:17Speaker 5: trying to cut out the middleman and the PBM. They
- 41:21Speaker 5: are in a lot of retail pharmacies now. In addition,
- 41:25Speaker 5: they have partnered with a male Factor Fertility Specialists who's
- 41:30Speaker 5: based here in Colorado, which is where I.
- 41:33Speaker 4: Am, and.
- 41:36Speaker 5: They've partnered together to try to because none are given
- 41:41Speaker 5: these medications too for certain hormone deficiencies or if they
- 41:46Speaker 5: have issues with spermatogenesis. And it's the same process, right,
- 41:50Speaker 5: It's the hypothelemic pituitary testicular access as opposed to the
- 41:55Speaker 5: hypothalamic pituitary ovariant access, but it's the same thing.
- 41:58Speaker 4: So the medications are the same. And so I see,
- 42:02Speaker 4: not only.
- 42:03Speaker 5: Are they cutting out the middle man of the PBM,
- 42:05Speaker 5: which is saving we know the PBMs in rebates and
- 42:09Speaker 5: it's really complicated and the money flows really hard to
- 42:12Speaker 5: understand and it's difficult, but they're kind of cutting that out.
- 42:15Speaker 4: Not only that, they're making.
- 42:17Speaker 5: Sure that pharmacists are being reimbursed for their services, and
- 42:22Speaker 5: they're really pushing for that, which is all around the country,
- 42:25Speaker 5: which is so phenomenal. I just I think that So
- 42:30Speaker 5: I was an unpe and I could bill for all
- 42:33Speaker 5: my services before I.
- 42:34Speaker 4: Became a pharmacist.
- 42:35Speaker 5: When I got to the pharmacy, and I was doing
- 42:38Speaker 5: MTM with medication therapeutic management, medication therapy management, which is
- 42:44Speaker 5: what a lot of pharmacists do.
- 42:46Speaker 4: That's their whole life.
- 42:47Speaker 5: And really they should be able to build for it,
- 42:50Speaker 5: right and in some states they can, but let's vaccinations,
- 42:57Speaker 5: all the counseling, you know, and and states they can
- 43:00Speaker 5: actually prescribe birth control, like where are where are.
- 43:05Speaker 4: These pharmacists being able to build and.
- 43:07Speaker 5: When are they going to be able to build and
- 43:08Speaker 5: be recognized for the contribution they make to not only
- 43:13Speaker 5: fertility but in other specialties but all over right. I
- 43:19Speaker 5: have a huge appreciation for it because I have been
- 43:24Speaker 5: in both roles, and I.
- 43:25Speaker 4: Would say it's the same.
- 43:27Speaker 5: Pharmacists are doing so much work, and to see them
- 43:31Speaker 5: be able to contribute more understand these specialty disease states,
- 43:36Speaker 5: and we're going to need more pharmacists and fertility, so
- 43:38Speaker 5: that that would be helpful. But to see them be
- 43:42Speaker 5: really recognized and be able to be financially compensated.
- 43:47Speaker 4: For the work that they're doing, I'm so passionate about that.
- 43:50Speaker 3: Clearly, thank you.
- 43:51Speaker 1: I really appreciate that because while pharmacists traditionally are doing
- 43:55Speaker 1: these services, they're paid an hourly wage from the corporation
- 43:58Speaker 1: for which they work, not in the same manner of reimbursements,
- 44:02Speaker 1: which are MD's your doos. And I live in Nevada
- 44:05Speaker 1: where nurse practitioners can practice autonomously, so it's one of
- 44:10Speaker 1: the things for me to get a pharmacogenetic test done
- 44:15Speaker 1: for a patient. I have to collaborate with a third
- 44:19Speaker 1: party to get that test ordered. And it didn't make
- 44:24Speaker 1: sense to me that I have a doctorate degree over
- 44:26Speaker 1: eight years, you know, a dozen years out in actual practice,
- 44:32Speaker 1: and I can't order that PGC test. Now, like you said,
- 44:35Speaker 1: it is specific, there's no consistency. So I know pharmacists
- 44:39Speaker 1: in other states can order the test. But my workaround
- 44:43Speaker 1: for that was the patient orders it on their own
- 44:46Speaker 1: through a different I have recommendations, I have different labs
- 44:50Speaker 1: I work with. I'm not specific to one lab, and
- 44:52Speaker 1: then they hire me as their consultant. But it's the
- 44:55Speaker 1: patient that's paying for my consultancy. I should be able
- 44:58Speaker 1: to reimburse for that through the insurances. So that's the goal, right,
- 45:03Speaker 1: I agree, And I want to mention and you mentioned
- 45:06Speaker 1: as RM, So that's the American Society for Reproductive Medicine.
- 45:12Speaker 1: What can you tell me about this society because I'm
- 45:14Speaker 1: not familiar with them.
- 45:15Speaker 5: Yeah, the ASRM is the governing body behind the fertility
- 45:21Speaker 5: Really is a nonprofit organization. It's over seventy five years old,
- 45:27Speaker 5: so it's been around for a really long time, well
- 45:30Speaker 5: before the first IBF baby was born, which was nineteen
- 45:33Speaker 5: seventy eight in London. So you know, we've had this
- 45:37Speaker 5: society and it really is a labor of love for
- 45:42Speaker 5: those who work for the ASRM because again it is
- 45:46Speaker 5: a nonprofit. They specialize in education. They have a whole
- 45:51Speaker 5: educational program now for APPS that they they're launching along
- 45:58Speaker 5: with a certification that's through the ncc A nursing governing
- 46:04Speaker 5: body that's for primarily for women's healthare's practitioners, but the
- 46:09Speaker 5: test can be taken and it can be to give
- 46:11Speaker 5: them a certification because as I mentioned, APPS are going
- 46:15Speaker 5: to be doing.
- 46:15Speaker 4: More in the space, so that's one area.
- 46:18Speaker 5: But they also have you know an oncofertility professional groups,
- 46:23Speaker 5: so all these sub professional groups like pcos and male
- 46:28Speaker 5: Factor and so there's genetic testing. Our genetics people in
- 46:31Speaker 5: fertility are amazing. They usually are in the form of
- 46:35Speaker 5: genetic counselors, so master's prepared. Often you'll see the PhDs
- 46:39Speaker 5: in the clinic doing embryo testing, so they're doing pg
- 46:44Speaker 5: TA so reimplantation genetic testing for an euploidy, so it's
- 46:50Speaker 5: for to look at the whole spectrum and they're using
- 46:53Speaker 5: next generation sequencing for those those services. But the genetic
- 46:58Speaker 5: counselors are amazing. They're not doing as much pharmacogenetic testing.
- 47:03Speaker 4: They're doing carrio typing.
- 47:05Speaker 5: So now they do a carriotype of over three hundred
- 47:07Speaker 5: different carrier for the male and female partner in the
- 47:14Speaker 5: as parents to see what they what they carry, so
- 47:19Speaker 5: you know, we know if they're both CF carriers, for example,
- 47:23Speaker 5: cystick fibrosis, but we can test for that now, and
- 47:26Speaker 5: then we can we can eliminate those embryos or just
- 47:29Speaker 5: not transfer those embryos, transfer the ones that are unaffected.
- 47:32Speaker 5: So you know, so that's where the carrio typing comes in.
- 47:36Speaker 5: So they're amazing. But you know, whenever I would get
- 47:39Speaker 5: a PGTA report back and it had some something from
- 47:43Speaker 5: single gene that I didn't very weird, I would hand
- 47:48Speaker 5: it to the genetic counselor and the clinic and their
- 47:50Speaker 5: eyes would light up because it was something that never,
- 47:52Speaker 5: you know, they didn't get to see very often. So
- 47:55Speaker 5: so you know, that's back circling back to the interdisciplinary.
- 47:59Speaker 4: But so ASRM supports these groups.
- 48:02Speaker 5: There's an ASRM law group because there's legal that our
- 48:06Speaker 5: lawyers that practice in the space, if anybody ever gets
- 48:10Speaker 5: a chance to one of them is Susan Kraken, and
- 48:16Speaker 5: there's others as well, but if anybody gets to listen
- 48:20Speaker 5: to one of them, they're amazing.
- 48:22Speaker 4: You know.
- 48:22Speaker 5: Her tagline is, you know, doctors make babies, the law
- 48:27Speaker 5: makes families. End a story, right, there's more to this story.
- 48:32Speaker 5: But she's been very.
- 48:35Speaker 4: Helpful.
- 48:36Speaker 5: Is this previous previous ASRM meeting that was held in
- 48:39Speaker 5: two thousand and twenty four, It was in Denver, but
- 48:43Speaker 5: to talk about the legislation that's happening with personhood laws
- 48:47Speaker 5: and all of those those sorts of things that are important.
- 48:50Speaker 5: So the CRM has this, you know, really big far
- 48:54Speaker 5: reach of interdisciplinary books that help fertility patients. One thing
- 48:59Speaker 5: they don't have that I would love to see that
- 49:01Speaker 5: I would love to champion is a pharmacist you know,
- 49:07Speaker 5: really have a pharmacist group, you know, a specialty pharmacy group,
- 49:12Speaker 5: because that would be a place where new pharmacists could
- 49:16Speaker 5: be trained. They could go into the ASRM and either
- 49:20Speaker 5: join it or you know, pay a small fee for
- 49:22Speaker 5: a course and take a course and get these certifications.
- 49:27Speaker 4: They don't have it yet.
- 49:28Speaker 5: So I'm going to work with ASRM that that's one
- 49:31Speaker 5: of the one of the many things that I would
- 49:33Speaker 5: love to see because I think that people, especially because
- 49:38Speaker 5: I can see the whole picture, just to show and
- 49:42Speaker 5: support that that is a notion that we need.
- 49:46Speaker 3: To be.
- 49:49Speaker 4: I think ASRM needs to support for one.
- 49:52Speaker 5: And second, I think that it's been pharmacists are not
- 49:56Speaker 5: part of it. So it's a little bit frustrating. I
- 49:59Speaker 5: don't think it's or just not paying attention to pharmacists.
- 50:02Speaker 5: I just think there wasn't I guess this understanding that.
- 50:05Speaker 4: I think they all just assumed that pharmacists no pharmacists
- 50:08Speaker 4: or taught this.
- 50:09Speaker 5: They're not, you know, trying to tell people that armacists,
- 50:12Speaker 5: I promise either or not taught this in pharmacy school.
- 50:15Speaker 4: They do not come out just knowing this, right.
- 50:17Speaker 5: So I think that that's really more the where the
- 50:22Speaker 5: disconnect is.
- 50:23Speaker 4: It's just that the assumption that pharmacists that we know.
- 50:26Speaker 1: Helly, what you're describing is parallel to every disease day, right,
- 50:30Speaker 1: Pharmacists have really had to advocate. You know, I'm a
- 50:32Speaker 1: third generation pharmacist, and my dad, my grandfather, my mom
- 50:36Speaker 1: used to say that pharmacists need better pr like you
- 50:40Speaker 1: know right. We've also had pushback from other associations. I
- 50:44Speaker 1: think like the AMA and whatnot over the years. But
- 50:47Speaker 1: that aside, it's on us to really advocate. Like you said,
- 50:50Speaker 1: it's almost not even a thought. Why did nobody think,
- 50:53Speaker 1: let's have a pharmacist. But I can see in other
- 50:56Speaker 1: disease states, like I mentioned oncology and oh my gosh,
- 51:00Speaker 1: so many other specialty psychiatry, that pharmacists now were really
- 51:04Speaker 1: stepping up and taking a role because the medications have
- 51:07Speaker 1: gotten complex, the pharmacodynamics, the pharmacokinetics are very complex, and
- 51:12Speaker 1: you're working with medications that take a deep understanding of
- 51:16Speaker 1: the science behind them, and as you mentioned, the process
- 51:20Speaker 1: to get the payers covering them.
- 51:22Speaker 3: And I just went back and looked.
- 51:25Speaker 1: So, while there's not a BOORD certification, the Board of
- 51:29Speaker 1: Pharmacy Specialties does not offer anything in fertility. I remember
- 51:33Speaker 1: at least saying that they do have within one of
- 51:35Speaker 1: their tracks guidelines to understand.
- 51:38Speaker 3: To be part of a different certification.
- 51:41Speaker 1: And I see that the ASHP SO, your Americanciety of
- 51:45Speaker 1: Health System Pharmacists, offers a specialty pharmacy certificate with the
- 51:49Speaker 1: Family Fertility Management track and something called PRECEE I'm not
- 51:54Speaker 1: familiar with. How's a reproductive infertility care specialty certificate programs,
- 51:58Speaker 1: so let's look into those and maybe they'll partner with
- 52:02Speaker 1: ASRM And that's right, doual certificate would be the dream, right.
- 52:07Speaker 5: And I am also I'm speaking at the Colorado Pharmacist
- 52:11Speaker 5: Society meeting this year in June, and it is to
- 52:15Speaker 5: teach pharmacists about you go to our state meeting about fertility.
- 52:23Speaker 4: Pharmacy, like what's involved.
- 52:26Speaker 5: And I have, you know, my fun cartoons because it's
- 52:28Speaker 5: a it's a PowerPoint presentation. So I'm hoping to be
- 52:31Speaker 5: able to increase some understanding and awareness in the state
- 52:34Speaker 5: of Colorado for that and hopefully you know, it doesn't
- 52:38Speaker 5: stop there. I know that the a s HP has certifications.
- 52:44Speaker 5: I did go through those and got certified myself just
- 52:47Speaker 5: to make sure I knew what was out there. And
- 52:50Speaker 5: it's it's good. It's offered though by a pharmacist who's
- 52:55Speaker 5: who is in the specialty space for pharmacy, so they
- 52:59Speaker 5: have a good understanding. But I think having it from
- 53:03Speaker 5: a healthcare provider or your prescriber explain like this is
- 53:09Speaker 5: why you know, like we didn't even get through all
- 53:11Speaker 5: the different adjuncts like DHA testosterone for females and so
- 53:18Speaker 5: and supplements, and there's supplement cocktails that they give to
- 53:21Speaker 5: corresponders and all of a sudden, you know, the patient
- 53:25Speaker 5: comes up with, you know, this bag of you know,
- 53:28Speaker 5: here are my supplements, and I don't even know how many.
- 53:33Speaker 4: This is another area that I'm very.
- 53:34Speaker 5: Passionate about because I don't know how many doctors have
- 53:37Speaker 5: looked at you know, what kind of you know, inhibitors,
- 53:42Speaker 5: you know, we know we metabolic pathways or you know,
- 53:46Speaker 5: medications that they're taking. And it's a lot of fertility
- 53:50Speaker 5: patients are generally healthy. They're not taking blood pressure medications,
- 53:54Speaker 5: they're not taking statins.
- 53:56Speaker 4: Of course that would be contraindicated.
- 53:58Speaker 5: But they're not taking a whole bunch of things, so
- 54:01Speaker 5: they don't have to worry so much about that. But
- 54:03Speaker 5: how many of these supplements are you know, going against
- 54:07Speaker 5: one another.
- 54:07Speaker 4: I don't think any. You know, we don't get a lot.
- 54:10Speaker 5: Actually great was good with I thought with pharmacis with supplements.
- 54:14Speaker 5: Our supplement guy, we taught us a.
- 54:16Speaker 4: Lot of good stuff. But doctors don't get anything for supplements.
- 54:20Speaker 5: So they're just saying el larginine, there's evidence here, you go, melatonin,
- 54:25Speaker 5: there's evidence here, you go, you know, and it's it's
- 54:28Speaker 5: endless that the the things that are being prescribed, and
- 54:32Speaker 5: I think this is where pharmacists could come in and
- 54:34Speaker 5: say and even teach the providers the prescribers like, you know,
- 54:40Speaker 5: these are things that need to be checked out and
- 54:43Speaker 5: this is an area where a pharmacists would be great
- 54:45Speaker 5: to help, you know, to sit down with now, Grit,
- 54:49Speaker 5: I'm talking like pharmacists have all the time in the world.
- 54:52Speaker 4: They don't, but it would.
- 54:55Speaker 5: Be great, you know, if we could increase the amount
- 54:59Speaker 5: of pharmacists there are so that there is more time,
- 55:02Speaker 5: or even have pharmacists in roles that they're not necessarily
- 55:07Speaker 5: filling the orders, but they're a counselor, right, but let's
- 55:12Speaker 5: get them reimbursed for that.
- 55:15Speaker 1: Absolutely, and it goes back to when we have that
- 55:17Speaker 1: perception of pharmacists not having all the time in the world.
- 55:19Speaker 1: We're talking about the retail setting owned by corporations that
- 55:24Speaker 1: are very profit driven, and we're not talking about the
- 55:28Speaker 1: consultants that are educating a space. Absolutely, yeah, absolutely does exist.
- 55:35Speaker 1: And I want to mention how complex this is. And
- 55:39Speaker 1: when I say complex, you can't just look up a
- 55:42Speaker 1: medication in a drug resource and say it's safe or
- 55:46Speaker 1: not safe. So we were taught that statins are contraindicated
- 55:50Speaker 1: in pregnancy. However, there's a study that just came out
- 55:54Speaker 1: last year the role of pravast statin in preventing pre
- 55:57Speaker 1: acclampsy and high risk pregnant women, and a meta analysis
- 56:02Speaker 1: showed that it actually does.
- 56:03Speaker 3: And I don't know where this stem from.
- 56:06Speaker 6: It was a name liver maybe yep Xus study, And
- 56:10Speaker 6: I thought, who thought to get pravistat and to pregnant
- 56:14Speaker 6: women in a study because we were taught it's contraindicated.
- 56:17Speaker 1: So you know, we look at these new guidelines where
- 56:20Speaker 1: it's not ABCDX anymore.
- 56:23Speaker 3: How do we decide?
- 56:25Speaker 1: And that's why we're not talking about the pharmacists at
- 56:27Speaker 1: the retail space in moving forward in the future that
- 56:30Speaker 1: has about thirty seconds a ligne at a double drive through,
- 56:34Speaker 1: people standing at the counter with ice cream melting and
- 56:38Speaker 1: insurance yeah, giving whole family backs, right, that's not the
- 56:43Speaker 1: time and place. But for those pharmacists that are in
- 56:47Speaker 1: that space, ask those patients do you feel that you
- 56:52Speaker 1: understand these medications? Let's set a time or make an
- 56:55Speaker 1: appointment where I can go over these and more detail
- 56:58Speaker 1: with you right, and that's that space, and it circles
- 57:01Speaker 1: back to that inter collaborative, interdisciplinary teamwork so that everyone
- 57:07Speaker 1: feels confident empowered through this process. I have one more
- 57:12Speaker 1: question for you. What do you wish more people knew
- 57:15Speaker 1: about IVF?
- 57:17Speaker 4: I would say this is tough because it's hard. It's
- 57:20Speaker 4: so I've.
- 57:21Speaker 5: Seen so many different people from all locks of life
- 57:25Speaker 5: and coming into IVF without knowledge. I think in the
- 57:32Speaker 5: areas like the States with a mandate, there's not a
- 57:36Speaker 5: lot of research done by the patients because they're not paying.
- 57:40Speaker 5: Patients who pay do more research, so they have that
- 57:45Speaker 5: different But I think that people in general should know
- 57:50Speaker 5: that it is it's not rock, it's not mad scientists
- 57:54Speaker 5: running around in a lab. This is this is healthcare, right.
- 57:58Speaker 5: This is just as much part of healthcare as getting
- 58:03Speaker 5: your chemotherapy if you have cancer.
- 58:07Speaker 4: It really is.
- 58:08Speaker 5: Infertility is a disease. You know, they tried to shut
- 58:11Speaker 5: down the clinics during the pandemic because they said, you know,
- 58:15Speaker 5: these are these patients aren't sick. They this is an
- 58:19Speaker 5: elective process, and there was a huge public outcry. The
- 58:25Speaker 5: SRM was very helpful and you know, making sure that
- 58:28Speaker 5: the advocacy groups. You know, there's a lot of patient
- 58:30Speaker 5: advocacy groups out there that are really pushed for it
- 58:35Speaker 5: and allowed the clinics to be reopened. And they, of
- 58:41Speaker 5: course once they were reopened, not only did they have
- 58:45Speaker 5: a flood a backflow of patients waiting for treatment, but
- 58:49Speaker 5: they also had all of these women now who were
- 58:51Speaker 5: working from home and said, oh.
- 58:53Speaker 4: I can have a baby now.
- 58:55Speaker 5: So it was madness of the clinics at flute madness.
- 58:58Speaker 5: So I think that, you know, it was a really
- 59:01Speaker 5: big lesson to some people during the pandemic that this
- 59:04Speaker 5: is not something like, Okay, we're shutting down the botox clinics. Yes,
- 59:09Speaker 5: that is elective. Well, I take it back, it's elective
- 59:12Speaker 5: when it's for aesthetics. There's botox treatment for certain off
- 59:16Speaker 5: label for certain That is medical care. But it's not
- 59:20Speaker 5: just some elective. You know, you can't have your hair
- 59:25Speaker 5: done today, or you can't have your botox injected into
- 59:28Speaker 5: your forehead. It's it's medical care, just like anything else.
- 59:33Speaker 1: And I really appreciate I think that's the most important
- 59:35Speaker 1: takeaway that if we can get this looked at just
- 59:38Speaker 1: like we do these other disease states, and I remember
- 59:42Speaker 1: last year when in Alabama some clinics were shut down
- 59:45Speaker 1: and these women that had gone through that. You know,
- 59:48Speaker 1: and our listeners can't see your reaction right now, but
- 59:50Speaker 1: as soon as I mentioned, like, I get chills and
- 59:52Speaker 1: I saw you like catch your breath because it's just
- 59:55Speaker 1: so hard to understand that this is politicians are making
- 59:59Speaker 1: these decisions for families, right the science that they were
- 1:00:05Speaker 1: stating was inaccurate.
- 1:00:07Speaker 3: It was actually completely false. It wasn't slightly inaccurate.
- 1:00:10Speaker 1: And in the implications to these families you mentioned through
- 1:00:13Speaker 1: this hour, what it is they go through, what the
- 1:00:15Speaker 1: women go through, the families, the community, the doctors, the pharmacists,
- 1:00:20Speaker 1: the nurses.
- 1:00:21Speaker 3: Everyone involved in this process.
- 1:00:22Speaker 1: And if we can take anything away from this, let's
- 1:00:26Speaker 1: get pharmacists really understanding this. Regardless of where in the
- 1:00:30Speaker 1: role you play in that patient's journey, whether you're in
- 1:00:33Speaker 1: a dispensing role, a consulting role, an education role, supportive role.
- 1:00:38Speaker 1: If you have coworkers, family friends, understand you're there for them.
- 1:00:42Speaker 3: We can do whatever we can.
- 1:00:44Speaker 1: To support them and have these positive outcomes.
- 1:00:49Speaker 3: These numbers are huge.
- 1:00:51Speaker 1: You mentioned the specialists I go through twelve to fifteen
- 1:00:54Speaker 1: years of education, for this are so limited, nowhere near
- 1:00:58Speaker 1: the number that is support and pharmacists are in that.
- 1:01:01Speaker 3: Space to fill that gap. Kelly, thank you so much.
- 1:01:07Speaker 1: I do want to ask you mentioned in Denver is
- 1:01:09Speaker 1: in Denver coming up? You have a seminar for ASHP members.
- 1:01:14Speaker 5: So it's for the Colorado Pharmacist Society meeting. So it'll
- 1:01:18Speaker 5: be part of the on demand content for that meeting.
- 1:01:20Speaker 1: Okay, and that's in June of twenty twenty five, correct, Yes, okay, perfect?
- 1:01:25Speaker 1: Anything else you'd like to share about what you do?
- 1:01:28Speaker 1: How anyone can find you if they like more information,
- 1:01:32Speaker 1: So you.
- 1:01:32Speaker 4: Can find me on LinkedIn.
- 1:01:34Speaker 5: I don't know if there's that many Kelly gandas out
- 1:01:36Speaker 5: there at this point. I am looking at lots of
- 1:01:40Speaker 5: different areas where I'd like to consult. One being in
- 1:01:45Speaker 5: the fertility clinic, because as I mentioned all the things
- 1:01:49Speaker 5: we talked about, the fertility clinics are going to be
- 1:01:53Speaker 5: pretty backlogged if all these orders and mandates come through
- 1:01:57Speaker 5: and there's already interprofessional in the clinic. Oftentimes not always,
- 1:02:03Speaker 5: because some clinics run very well and do interprofessional very well,
- 1:02:09Speaker 5: but not all of them do a lot of times
- 1:02:12Speaker 5: they're working in silos, So nursing is working over here
- 1:02:15Speaker 5: and realogy is working over here, and they're really not
- 1:02:19Speaker 5: coming together right in a way that is the best
- 1:02:23Speaker 5: way to take care of patients. And there's a lot
- 1:02:29Speaker 5: of inefficiencies because of that. And I'll put a plug
- 1:02:32Speaker 5: into none of my favorite, favorite favorite scientists, and it's
- 1:02:36Speaker 5: Amy Edmonton. She wrote a book called She's written lots
- 1:02:39Speaker 5: of books, but my favorite one's The Right Kind of Wrong,
- 1:02:41Speaker 5: and she studies how medication.
- 1:02:43Speaker 4: Errors are systemic errors or are they personal errors? Where
- 1:02:50Speaker 4: do they come from?
- 1:02:51Speaker 5: That She talks a lot about psychological safety, but she
- 1:02:54Speaker 5: also talks a lot about the teamwork that's involved in
- 1:02:58Speaker 5: medical care, not just to prevent errors, but to catch
- 1:03:05Speaker 5: inefficiencies or things that go wrong on the fly and
- 1:03:09Speaker 5: work as a team. And there's so much research behind
- 1:03:14Speaker 5: her what she calls teaming. And I don't know if
- 1:03:20Speaker 5: she's got a trademark on it or not, but I'm
- 1:03:22Speaker 5: going to say it's hers, it's teaming. And I would
- 1:03:24Speaker 5: love to see fertility clinics utilize some of these methods
- 1:03:29Speaker 5: because I think that not only would there be happier
- 1:03:33Speaker 5: providers or happier nurses, I think there would be a
- 1:03:36Speaker 5: better patient retention. And patients, you know, are jumping from
- 1:03:39Speaker 5: clinic to clinic, and that's a whole other you know,
- 1:03:42Speaker 5: because they want to find that that perfect, they want
- 1:03:45Speaker 5: to get their baby, and if things don't seem to
- 1:03:48Speaker 5: be going right in the clinic, you know, they have
- 1:03:50Speaker 5: other choices if they live in a metropolitan area.
- 1:03:53Speaker 4: Not all patients have a lot of choices.
- 1:03:56Speaker 5: Like if you live in Wyoming, you don't have a
- 1:03:58Speaker 5: lot of choice, right, So I think that there's a
- 1:04:00Speaker 5: lot of holes in our country. But that's something that
- 1:04:04Speaker 5: I'm really interested in and I would love to see and.
- 1:04:09Speaker 4: Be able to be part of that.
- 1:04:10Speaker 5: But but I feel like there's other things I'm so
- 1:04:13Speaker 5: interested and passionate about, which I already talked about on
- 1:04:15Speaker 5: this podcast, with you know, educating pharmacists, helping there be
- 1:04:21Speaker 5: more resources for pharmacists for fertility and to be have
- 1:04:26Speaker 5: ASRM have a group for them, and other consulting. I mean,
- 1:04:31Speaker 5: I would love, I love, I loved working with patients,
- 1:04:33Speaker 5: so that might come up in my future consulting efforts
- 1:04:39Speaker 5: as well.
- 1:04:40Speaker 1: So Doctor Kelly Ganda, fertility nurse, practitioner and pharmacist, thank
- 1:04:44Speaker 1: you so much for the incredible work you're doing in
- 1:04:47Speaker 1: this space of fertility and iv AP and I.
- 1:04:51Speaker 3: See a lot of opportunity for you out there to
- 1:04:53Speaker 3: fill all these gaps that we just discussed.
- 1:04:56Speaker 1: Thank you so much for taking time to speak today
- 1:04:58Speaker 1: and share your insight and support everyone out there going
- 1:05:02Speaker 1: through this. We look forward to reconnecting in the future
- 1:05:06Speaker 1: and looking back.
- 1:05:07Speaker 3: And showing that we fill those holes.
- 1:05:09Speaker 1: The educations there, the legislations there, and anyone who wants
- 1:05:13Speaker 1: to use IVF to grow their family has easy access
- 1:05:16Speaker 1: to do so. If anyone found yeah, absolutely, if anyone
- 1:05:21Speaker 1: listening found this helpful, please do share it and a
- 1:05:24Speaker 1: shout out, a big shout out to the front